image: The virtual event will provide an in-depth look at major updates across key applications including PandaOmics, Generative Biologics, Chemistry42, Science42: DORA, and PreciousGPT, through interactive demos and real-world case studies.
Credit: Insilico Medicine
Alex Zhavoronkov, PhD, founder, CEO & CBO of Insilico Medicine, was recently named to the Observer A.I. Power Index 2025 for his contributions to biotechnology breakthroughs driven by AI, with the validation and release of Pharma.AI as one of the top achievements. Initiated in 2016, Pharma.AI is a comprehensive generative AI-powered drug discovery platform spanning biology, chemistry, medicine development, and scientific research. In addition to being licensed by 13 of the top 20 pharmaceutical companies, Pharma.AI has also empowered Insilico's 30+ innovative internal pipelines.
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announces the third edition of its Pharma.AI quarterly launch series on October 2, 10:00-11:00 a.m. EST. The virtual event will provide an in-depth look at major updates across key applications including PandaOmics, Generative Biologics, Chemistry42, Science42: DORA, and PreciousGPT, through interactive demos and real-world case studies.
Step into the future of pharmaceutical innovation with Insilico, Register for Pharma.AI Fall Updates at:
https://insilico.zoom.us/webinar/register/3017580990625/WN_IzqS_ZtfTpiQkixqqpMrvg#/registration
Key Platform Highlights Include:
PandaOmics for Target and Biomarker Discovery: PandaOmics becomes even more intelligent with the integration of four novel LLM scores, utilizing large language models to better assess and validate disease targets. Moreover, newly added features including dataset sharing, gene signature analysis and single-cell data viewer will hopefully make the research process more efficient, more precise, and more visualized.
Generative Biologics for Biologics Engineering: Generative Biologics takes a major leap forward with enhanced contact analysis and visualization, for a deeper understanding of antigen-antibody interactions. This is paired with advanced 3D predictive model training and an automated liability detection and filtering feature.
Chemistry42 for Small Molecule Design and Optimization: For more sophisticated control over the generation process, Chemistry42 now allows researchers to select specific protein-based pharmacophores as constraints, guiding the AI to generate more targeted molecules. More importantly, the platform introduces MDFlow, the new molecular dynamics (MD) simulation application for biomolecules and protein–ligand complexes.
Science42: DORA for Scientific Research: DORA, the writing assistant based on multiple AI agents, receives a significant AI core upgrade with state-of-the-art generative model. As for functions, DORA is also enhanced with smart citations and expanded integrations, so as to further streamline scientific publication processes.
PreciousGPT Series for Disease Modelling, Drug Discovery, and Others: Insilico research team will share insights from two new peer-reviewed papers on ipf-Precious the disease-specific AI research toolset, and the strategy of finding dual-purpose targets, respectively. Also, Insilico Longevity Vault, a curated collection of priority targets for anti-aging drug development will be publicly released, and geroprotective potential analysis of Insilico’s clinical-stage pipelines can be expected in the near future.
Join Insilico on October 2nd, 2025 to be the first to see cutting-edge innovations in AI-driven R&D, and gain insights into how integrated platforms are redefining the exploration boundaries in pharma!
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com